KRTX Stock Price, Chart, Stats & News
Karuna Therapeutics, Inc. (KRTX) does not currently pay a dividend.
KRTX chart
Fundamentals
Gross margin | -160.09% |
Operating margin | -75653.98% |
Pretax margin | -66209.48% |
Net margin | -66311.93% |
Effective tax rate | -0.15% |
ROA | -32.46% |
ROE | -36.44% |
D/E | 0.01x |
Interest coverage ratio | – |
KRTX valuation
P/E | – |
P/S | 19264.95x |
P/B | 9.72x |
P/CF | -31.60x |
P/FCF | -32.41x |
P/OCF | -31.60x |
PEG | -0.28x |
EV multiple | -25.90x |
About
Operating as a clinical-stage biopharmaceutical firm, Karuna Therapeutics, Inc. is dedicated to pioneering innovative therapies for individuals afflicted by psychiatric and neurological disorders. Its primary investigational compound, KarXT, is an oral agent designed to modulate muscarinic receptors. Currently in Phase III clinical trials, KarXT is being evaluated for several indications: the treatment of acute psychosis in schizophrenia patients, the amelioration of central nervous system conditions (including the negative and cognitive symptoms associated with schizophrenia and general psychosis), and the management of dementia-related psychosis.
Similar securities
Based on sector and market capitalization
